Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates
In addition, we look forward to submitting our second IND application for MuSK-CAART, our lead preclinical candidate, in the second half of 2021.
- In addition, we look forward to submitting our second IND application for MuSK-CAART, our lead preclinical candidate, in the second half of 2021.
- "\nToday, the Company reported results from the first cohort of three patients dosed with DSG3-CAART.
- Cabaletta expects to announce acute safety data for the second and third cohorts in the third and fourth quarters of 2021, respectively.
- Topline data on target engagement from the first cohort are anticipated during the second half of 2021.